An observational study in Bronchial Asthma, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-21.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Asthma with a site in Egypt — 10 open to participants now, 11 under way, 1 of them phase 3. Asthma · Egypt.
Among the 42 studies in Asthma with a site in Egypt, this one is the 4th largest by planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2023, is one of 17 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 23rd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →10 of the 42 studies in Asthma with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–30 · Women only
AstraZeneca · Sites in Egypt, Argentina, Mexico and 4 more countries
Ages 18+
Sohag University · Sites in Egypt
Ages 4–12 · Healthy volunteers
Sohag University · Sites in Egypt
Ages 2–18 · Healthy volunteers
Sohag University · Sites in Egypt
Ages 2–18
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 4 · Phase 4 2
First in 2012; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 65 across the 25 interventional studies, 137 across the 17 observational. Of the 26 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 42 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 7 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
3 of the studies in Asthma with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07730047Shaimaa Ali MohammedNLR, ELR and SII Index as Biomarkers of Asthma Control | 2027-01-01 |
| NCT07896291Sohag UniversityPrevelance of Bronchial Asthma and Allergic Rhinitis Among Children With Nephrotic Syndrom at Sohag University Hospital | 2027-03-01 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Asthma with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Asthma is a significant public health threat, affecting more than 300 million individuals globally. Asthma is classified as a non-communicable disease and leads to reduced quality of life, poor physical functioning and reduced emotional well-being. The impact of this disease can be widespread and extends beyond the person living with the disease, affecting the lives of their family members, carers, communities and the health care system (1).
Asthma is a variable chronic respiratory condition. It is characterized by symptoms of wheeze, cough, chest tightness, dyspnea and backed by variable airflow limitation, airway inflammation and airway hyper-responsiveness (AHR). The severity of asthma varies considerably, both between individuals and within individuals over time. Some people may have intermittent asthma and others may experience severe, potentially life-threatening disease (2, 3,4).
bronchial asthma patients aged more than 18 years of both sexes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
group A (controlled bronchial asthma patients)
Drug: corticosteroids
group B(uncontrolled bronchial asthma patients)
Drug: corticosteroids
inhailed or oral corticosteroids
percent of controlled bronchial asthma patients
to detect percent of controlled patients
Time frame: 12 months
Started Nov 2023 (actual). Primary completion is estimated for Dec 2024, 13 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 13 months is below that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.